OmniAb (OABI) Q4 2025 earnings review
A Transitional Year Ends with a Guide for a Sharp Rebound
OmniAb's 2025 financial picture was defined by the roll-off of legacy service contracts and lumpy milestone timing, pushing full-year revenue down 29% YoY. However, Q4 showed early signs of stabilization with $8.4M in revenue, reversing the severe top-line weakness seen in Q2 and Q3. Management is guiding for an accelerating FY26, projecting a 47% revenue jump at the midpoint to $25-$30M. While the core partner pipeline is maturing nicely with 32 clinical assets, execution risks remain glaring: the highly touted xPloration instrument launch appears to have completely stalled, and legacy business impairments continue to weigh on the bottom line.
🐂 Bull Case
The painful comparison against 2023/2024 deferred revenue and legacy contracts is largely over. FY26 guidance of $25-$30M indicates management has visibility into meaningful milestone triggers and new platform access fees.
The core engine remains healthy. OmniAb exited 2025 with 107 active partners and 407 active programs, ensuring a widening funnel of potential future royalties.
🐻 Bear Case
After a heavily promoted launch in early 2025 resulting in $608k of Q2 revenue, xPloration sales plummeted to just $30k in Q4. This implies zero new instruments were sold in the back half of the year, contradicting the narrative of a robust new recurring revenue stream.
The company ended FY25 with $54M in cash and expects to end FY26 with $30-$35M. A ~$20M annual cash burn leaves limited runway beyond 2027 if anticipated clinical milestones fail to materialize.
⚖️ Verdict: ⚪
Neutral. The FY26 guidance is a strong positive signal that the revenue floor has been established. However, the failure to gain traction with xPloration hardware and ongoing legacy impairments demand a 'show-me' approach until cash flow organically turns positive.
Key Themes
The xPloration Growth Engine Stalled
Management launched the xPloration instrument in early 2025, claiming strong partner interest and a robust sales funnel for the ~$500k units. The data tells a definitively reversing trend: after a $608k peak in Q2, Q3 generated only $74k, and Q4 saw a mere $30k (likely just consumables). This suggests that partners are entirely deferring capital expenditures or rejecting the in-house hardware model altogether.
OmniUltra Platform Launch Expands TAM
The Q4 launch of OmniUltra (a transgenic chicken engineered to express ultralong CDRH3 domains) is a significant technological leap. By enabling the isolation of 'picobodies' (which are one-third the size of nanobodies), OmniAb is opening up a completely new licensing market for peptide therapeutics, bispecifics, and radioligands. Management notes this requires direct service contracts, which should drive near-term service revenue.
Legacy Business Cleanup is Still Costing Money
OmniAb took a $3.9 million impairment charge in Q4 primarily related to small molecule ion channel property and equipment. While management strategically pivoted away from this business model in 2024 to focus on core antibody competencies, this late-stage write-down indicates that the balance sheet is still absorbing the cost of past strategic missteps.
Clinical Pipeline Maturation Accelerating
The primary driver of long-term value remains the clinical progress of partners. The company has 32 active clinical programs. Heavy hitters are advancing: Immunovant’s IMVT-1402 has a Phase 2 proof-of-concept readout expected in H2 2026, and Teva’s TEV-408 has Phase 1b/2a data readouts slated throughout the year. Merck KGaA also announced plans to advance the M9140 ADC to Phase 3 in 2026.
Macro Impact: Partner Capital Expenditure Restraints
While OmniAb is somewhat insulated from consumer macroeconomics, it is highly exposed to biotech capital budgeting. The complete drop-off in xPloration hardware sales in H2 2025 strongly suggests that smaller and mid-sized biotech partners are severely constricting their internal laboratory capex budgets, preferring to outsource discovery rather than buy expensive hardware.
Other KPIs
Stable and compounding. The total number of active programs grew from 363 at the end of FY24 to 407 at the end of FY25. This consistent expansion is the ultimate leading indicator for future milestone and royalty generation.
Decelerating year-over-year from $26.7M in 24Q4, reflecting the impact of headcount reductions and lower share-based compensation, partially masked by the $3.9M impairment charge. Management has successfully right-sized the operational footprint.
Guidance
Accelerating. The midpoint of $27.5M represents a 47% increase over FY25's $18.7M. This guide suggests the 'trough' of the deferred revenue roll-off has passed, and new milestone payments and platform access fees are expected to significantly re-accelerate the top line.
Stable to slightly decreasing. This compares favorably against the $87.6M in total costs reported for FY25. Crucially, the company guided to $50M - $55M in non-GAAP cash costs, indicating that approximately $30M of expenses will be non-cash (amortization and stock-based compensation).
Decelerating cash balance. Starting with $54.0M at the end of 2025, this implies an annual cash burn of roughly $19M to $24M. At this burn rate, OmniAb is fully funded through 2027 but will eventually require organic cash flow inflection or outside capital if milestone revenue stalls again.
Key Questions
xPloration Commercial Strategy
With xPloration hardware sales dropping to zero in the second half of the year, is the company considering a shift from a capital equipment sales model to a reagent-rental or pure service-based model to lower the adoption barrier for partners?
Legacy Impairments
Does the $3.9 million impairment on small molecule ion channel equipment in Q4 represent the final write-down for this discontinued strategic direction, or are there remaining legacy assets on the balance sheet at risk?
OmniUltra Monetization
Given that OmniUltra allows for the isolation of 'picobodies' and access to the peptide therapeutic market, how will the economics of these deals differ from standard OmniAb antibody licenses?